GlassScriptPhysician profile
Susan A Glenn
NPI 1538191341
$1,375.30
in general payments reported to CMS, 2019-2025
32 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $109 · 2021: $183 · 2022: $90.90 · 2023: $200 · 2024: $285 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.81 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $163.33 | 2019-2025 | |
| Amgen INC. | $141.21 | 2019-2020 | |
| Boston Scientific Corporation | $133.94 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2024 | Ultomiris |
| Allergan, INC. | $61.53 | 2019-2020 | |
| Ucb, INC. | $57.88 | 2019-2025 | Briviact |
| Lundbeck LLC | $47.26 | 2019-2020 | |
| Genzyme Corporation | $40.59 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $37.41 | 2023-2024 | Ingrezza, Ongentys |
| Microtransponder, INC. | $34.99 | 2023 | |
| Merz North America, INC. | $34.97 | 2019 | |
| Aucta Pharmaceuticals, INC. | $27.21 | 2024-2025 | Motpoly Xr |
| Ge Healthcare | $25.11 | 2023 | |
| Avanir Pharmaceuticals, INC. | $19.04 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $18.97 | 2019 | |
| Siemens Medical Solutions USA, INC. | $18.63 | 2024 | Biograph Vision 600 (8 Ring/64 Ct) |
| Mallinckrodt Enterprises LLC | $17.83 | 2019 | |
| Biogen, INC. | $17.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.10 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.84 | 2025 | Rexulti |
| Acorda Therapeutics, INC | $16.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.64 | 2019 | |
| Springworks Therapeutics, INC. | $16.15 | 2025 | Gomekli |
| Upsher-Smith Laboratories LLC | $16.00 | 2019 | |
| Celgene Corporation | $13.87 | 2022 | |
| Lilly USA, LLC | $13.68 | 2024 | Kisunla, Amyvid |
| Grifols USA, LLC | $13.49 | 2019 | |
| Emd Serono, INC. | $13.17 | 2020 | |
| Acadia Pharmaceuticals INC | $12.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.41 | 2021 | |
| Pfizer INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Glenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.